Rubius Therapeutics Inc

NASDAQ:RUBY  
6.86
+0.32 (+4.89%)
Other Pre-Announcement

Rubius Therapeutics Reports Q3 Loss Per Share Of $0.51

Published: 11/09/2020 14:36 GMT
Rubius Therapeutics Inc (RUBY) - Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline.
Q3 Loss per Share $0.51.
Q3 Earnings per Share Estimate $-0.49 -- Refinitiv Ibes Data (analyst estimates).
Rubius Therapeutics - As of Sept 30, 2020, Cash, Cash Equivalents and Investments Were $207.9 Million Providing Rubius With a Cash Runway Into 2022.